Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant or Letrozole, Based on Prior Endocrine Therapy, in Patients With PIK3CA Mutant, HR+, HER2- Advanced Breast Cancer Who Have Progressed on or After Prior Treatments
Clinical trial NCT03056755 · COMPLETED
Trial details
- NCT number
- NCT03056755
- Sponsor
- Novartis Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-08-29
- Primary completion
- 2021-06-14
- Enrollment
- 383
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.